Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Nippon Ganka Gakkai Zasshi|March 17, 2004
[Effect of various anti-glaucoma eyedrops on human corneal epithelial cells]Yumiko Aoyama, Masamitsu Motoki, Mariko Hashimoto
Biopharmaceutics & Drug Disposition|November 10, 2012
Lack of differences in the pharmacokinetics of sepantronium bromide (YM155) between US and Japanese patients with advanced solid tumors or non-Hodgkin lymphomaYumiko Aoyama, Masataka Katashima, Taiji Sawamoto
Japanese Journal of Ophthalmology|October 23, 2009
Relationship between central corneal thickness and visual field defect in open-angle glaucomaWenzhong Lin, Yumiko Aoyama, Kazuhide Kawase, et al.
Journal of Glaucoma|September 1, 2011
Macular retinal thickness in glaucoma with superior or inferior visual hemifield defectsHiroko Inuzuka, Kazuhide Kawase, Akira Sawada, et al.
Japanese Journal of Ophthalmology|December 31, 2010
Effects of timolol-related ophthalmic solutions on cultured human conjunctival cellsKazuhide Kawase, Wenzhong Lin, Yumiko Aoyama, et al.
Investigational New Drugs|August 16, 2012
Population pharmacokinetic modeling of sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanomaYumiko Aoyama, Atsunori Kaibara, Akitsugu Takada, et al.
Cancer Chemotherapy and Pharmacology|July 19, 2012
Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairmentYumiko Aoyama, Tetsuya Nishimura, Taiji Sawamoto, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|March 10, 2004
Effects of dorzolamide hydrochloride on ocular tissuesJun Inoue, Mikako Oka, Yumiko Aoyama, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumorsTaroh Satoh, Isamu Okamoto, Masaki Miyazaki, et al.
Therapeutic Innovation & Regulatory Science|May 2, 2018
Medical Writing Competency Model - Section 2: Knowledge, Skills, Abilities, and BehaviorsDavid B Clemow, Bertil Wagner, Christopher Marshallsay, et al.
Pageof 2